35,000 Shares in McKesson Co. (NYSE:MCK) Acquired by Integral Health Asset Management LLC

Integral Health Asset Management LLC purchased a new stake in shares of McKesson Co. (NYSE:MCK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 35,000 shares of the company's stock, valued at approximately $19,947,000. McKesson makes up approximately 1.7% of Integral Health Asset Management LLC's holdings, making the stock its 16th largest holding.

Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new position in McKesson in the 4th quarter valued at about $1,200,361,000. Farallon Capital Management LLC purchased a new stake in McKesson during the 4th quarter worth approximately $348,044,000. Marshall Wace LLP raised its position in shares of McKesson by 59,720.3% in the 4th quarter. Marshall Wace LLP now owns 358,922 shares of the company's stock valued at $204,553,000 after purchasing an additional 358,322 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of McKesson during the 4th quarter valued at approximately $178,397,000. Finally, Deutsche Bank AG grew its position in shares of McKesson by 64.0% during the fourth quarter. Deutsche Bank AG now owns 751,283 shares of the company's stock worth $428,164,000 after buying an additional 293,148 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Brian S. Tyler sold 8,961 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the completion of the transaction, the chief executive officer now owns 60,664 shares of the company's stock, valued at $36,276,465.36. This trade represents a 12.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.11% of the stock is currently owned by insiders.

McKesson Price Performance

Shares of NYSE MCK traded up $23.50 during midday trading on Thursday, hitting $705.78. 1,010,425 shares of the company's stock were exchanged, compared to its average volume of 912,604. McKesson Co. has a twelve month low of $464.42 and a twelve month high of $728.48. The firm has a market cap of $88.45 billion, a P/E ratio of 32.32, a PEG ratio of 1.29 and a beta of 0.53. The stock's 50 day moving average price is $680.82 and its 200-day moving average price is $623.83.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $10.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.83 by $0.29. The company had revenue of $90.82 billion during the quarter, compared to analyst estimates of $94 billion. McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. The firm's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.18 EPS. On average, analysts expect that McKesson Co. will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Shareholders of record on Monday, June 2nd will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, June 2nd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.40%. McKesson's dividend payout ratio (DPR) is 10.99%.

Analyst Ratings Changes

A number of research analysts have commented on MCK shares. UBS Group increased their price objective on shares of McKesson from $708.00 to $805.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Bank of America upped their target price on shares of McKesson from $755.00 to $800.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Cfra Research downgraded McKesson from a "moderate buy" rating to a "hold" rating in a research note on Friday, April 4th. Mizuho upped their price objective on McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a research note on Thursday, April 3rd. Finally, StockNews.com raised McKesson from a "buy" rating to a "strong-buy" rating in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, McKesson presently has an average rating of "Moderate Buy" and an average target price of $686.69.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.